Posted on December 12, 2022
Before we offer you this week’s home-made, risk-defined money-making mechanism, we have another trade to close.
It’s our ROL initiative from November 10th. The dispatch was called Rat Catchers Fall Flat…, and it urged you to sell the ROL December 16th 40/45 CALL spread for $1.05 and buy the ROL December 16th 40 PUT for $1.00. Total credit on the affair was a nickel.
The short 40 CALL can be repurchased for $0.20, and the long 40 PUT sold for $1.35.
Execute and you take home $1.20 on nothing spent.
Adjusted for minimum commissions gives you a haul of 700%.
In ONE month!
And now – with the hors d’oeuvres aside – we move to the main course.
We’re taking on the pharma-murderers again today. This time, it’s Bristol Myers Squiggle in the crosshairs (NYSE:BMY), a company we’ve slain in the past for some good scratch (673% and 187%).
So where does the stock get off trending at such heights…?
A recent study found that BMY’s Batflu medication, Eliquis, did nothing to help those suffering from even mild symptoms of the bug.
And analysts are paying attention—estimates for the stock have moved lower over the last 45 days.
Not a good sign, at all.
Once we reach that level, we’ll likely close, as the trade will be fully in-the-money.
May you walk with the G-d of Israel,
and may He bless you with all the wealth and simcha of which you’re worthy.
With kind regards,
Hugh L. O’Haynew